Fecal Microbiota Transplantation: The Evolving Risk Landscape

Area of Science:

• Microbiology
• Gastroenterology
• Infectious Diseases

Background:

• Fecal microbiota transplantation (FMT) is a recommended treatment for recurrent Clostridioides difficile infection (CDI).
• Despite clinical recommendations, FMT remains investigational, with increasing adoption raising safety concerns.
• Reported risks range from mild gastrointestinal issues to severe infections.

Purpose of the Study:

• To examine the evolving risk landscape of FMT.
• To address concerns regarding the safety profile of FMT as its use expands.
• To highlight the impact of varying screening approaches on FMT risk.

Main Methods:

• Review of current clinical guidelines and regulatory stances on FMT.
• Analysis of reported adverse events and safety concerns associated with FMT.
• Examination of screening methodologies and their influence on risk mitigation.

Main Results:

• FMT adoption has broadened, increasing awareness of potential risks.
• Variability in donor screening protocols impacts the overall safety profile.
• Recent cases of pathogen transmission underscore the need for enhanced screening.

Conclusions:

• Enhanced screening mandates, like those from the FDA, are crucial for safer FMT implementation.
• Standardizing donor testing is essential to minimize risks associated with FMT.
• Continued evaluation of the FMT risk landscape is necessary as the procedure becomes more widespread.